Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | DSS | Common Stock | 21.4M | Jul 12, 2022 | Direct | F1 | |||||
holding | DSS | Common Stock | 6.23M | Jul 12, 2022 | See Footnote | F2 |
Id | Content |
---|---|
F1 | 21,366,177 shares of the common stock of DSS, Inc. (the "Issuer") are held directly by Alset International Limited ("AIL"). These shares were acquired on July 12, 2022 pursuant to an assignment and assumption agreement (the "Agreement") between the Issuer and AIL dated February 28, 2022, as amended on July 12, 2022. Pursuant to the Agreement, as amended, the Issuer agreed to purchase a convertible promissory note from AIL (the "Note"). The Note has a principal amount of $8,350,000 and accrued but unpaid interest of $367,400. The Note was issued by American Medical REIT, Inc., a Maryland corporation. The consideration paid for the Note was 21,366,177 shares of the Issuer's common stock. The consideration was calculated by dividing $8,717,400, the aggregate of the principal amount and the accrued but unpaid interest under the Note, by $0.408 per share. |
F2 | 6,232,671 shares of the common stock of the Issuer are held by Global Biomedical Pte. Ltd., a subsidiary of AIL. |